# Lung Cancer Diagnosis and Treatment **Type:** Topics **Canonical URL:** https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/ ## Facts | Field | Value | | --- | --- | | Description | This cluster of papers focuses on the diagnosis and treatment of lung cancer, including topics such as CT screening, radiotherapy, chemotherapy, tumor staging, adjuvant therapy, positron emission tomography, stereotactic body radiation therapy, non-small cell lung cancer, and pulmonary nodules. | | Domain | Health Sciences | | Field | Medicine | | OpenAlex ID | t10202 | | Works | 823 | ## Topic papers all Showing 15 of 823. - [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/) - [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/) - [Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma](https://scholariq.org/papers/gefitinib-or-carboplatin-paclitaxel-in-pulmonary-adenocarcinoma/) - [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/) - [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/) - [Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer](https://scholariq.org/papers/paclitaxel-carboplatin-alone-or-with-bevacizumab-for-non-small-cell-lung-cancer/) - [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/) - [Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/) - [Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach](https://scholariq.org/papers/decoding-tumour-phenotype-by-noninvasive-imaging-using-a-quantitative-radiomics/) - [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/) - [The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer](https://scholariq.org/papers/the-iaslc-lung-cancer-staging-project-proposals-for-revision-of-the-tnm-stage/) - [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/) - [Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study](https://scholariq.org/papers/erlotinib-versus-chemotherapy-as-first-line-treatment-for-patients-with-advanced/) - [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/) - [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/) ## Topic primary papers Showing 15 of 268. - [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/) - [The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer](https://scholariq.org/papers/the-iaslc-lung-cancer-staging-project-proposals-for-revision-of-the-tnm-stage/) - [Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group](https://scholariq.org/papers/lung-adjuvant-cisplatin-evaluation-a-pooled-analysis-by-the-lace-collaborative/) - [Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy](https://scholariq.org/papers/prospective-randomized-trial-of-docetaxel-versus-best-supportive-care-in/) - [Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study](https://scholariq.org/papers/standard-dose-versus-high-dose-conformal-radiotherapy-with-concurrent-and/) - [Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/meta-analysis-of-concomitant-versus-sequential-radiochemotherapy-in-locally/) - [Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial](https://scholariq.org/papers/segmentectomy-versus-lobectomy-in-small-sized-peripheral-non-small-cell-lung/) - [Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial](https://scholariq.org/papers/adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-ib-iiia-non/) - [Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial](https://scholariq.org/papers/radiotherapy-plus-chemotherapy-with-or-without-surgical-resection-for-stage-iii/) - [American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003](https://scholariq.org/papers/american-society-of-clinical-oncology-treatment-of-unresectable-non-small-cell/) - [Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study](https://scholariq.org/papers/local-consolidative-therapy-vs-maintenance-therapy-or-observation-for-patients/) - [Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410](https://scholariq.org/papers/sequential-vs-concurrent-chemoradiation-for-stage-iii-non-small-cell-lung-cancer/) - [Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study](https://scholariq.org/papers/local-consolidative-therapy-versus-maintenance-therapy-or-observation-for/) - [Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation](https://scholariq.org/papers/characterisation-and-classification-of-oligometastatic-disease-a-european/) - [Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer/) --- Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.